MEDIKURA Revenue and Competitors
Estimated Revenue & Valuation
- MEDIKURA's estimated annual revenue is currently $3.5M per year.
- MEDIKURA's estimated revenue per employee is $112,000
Employee Data
- MEDIKURA has 31 Employees.
MEDIKURA's People
Name | Title | Email/Phone |
---|
MEDIKURA Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $13.3M | 95 | -35% | $14.1M | N/A |
#2 | $87.3M | 491 | -3% | $251M | N/A |
#3 | $15.5M | 111 | 11% | N/A | N/A |
#4 | $14.6M | 0 | N/A | $12.5M | N/A |
#5 | $32.8M | 213 | -6% | N/A | N/A |
#6 | $0.4M | 12 | 100% | $2.6M | N/A |
#7 | $55.3M | 316 | 2% | N/A | N/A |
#8 | $4.7M | 42 | -2% | N/A | N/A |
#9 | $431.2M | 2200 | 40% | N/A | N/A |
#10 | $45.9M | 298 | 4% | N/A | N/A |
What Is MEDIKURA?
MEDIKURA | The Future of Drug Safety: Digital Communication Infrastructure for Direct Exchange of Drug Side Effects & Innovative Software Solutions for Pharmaceutical/Biotech Companies & Healthcare Providers We are a dynamic young eHealth company and develop intelligent software applications, analysis tools and individual add-on services for pharmacovigilance. This enables the efficient recording, processing and evaluation of every incoming adverse drug reaction report, as well as the fast and secure initiation of necessary follow-up measures. * Gain valuable time through automated processes and seamless data integration. * Create trust through direct and secure exchange with patients and medical professionals. * Use valid real-world data for real-time drug monitoring and sound assessments of drug efficacy profiles. Join us in shaping the future of drug safety and learn more at www.medikura.com
keywords:N/AN/A
Total Funding
31
Number of Employees
$3.5M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.6M | 31 | -28% | N/A |
#2 | $3.6M | 31 | 29% | N/A |
#3 | $3.5M | 31 | -3% | N/A |
#4 | $3.2M | 31 | -43% | N/A |
#5 | $8.1M | 31 | 35% | N/A |